ArticleWorld journal of radiology2016
Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.
Article in World journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.Journal of clinical & translational endocrinology · 2026Review
- Inter-reader agreement and additive benefit of SPECT or SPECT/CT modality with [EJNMMI reports · 2025Article
- Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.World journal of gastroenterology · 2021Review
- Fusion iENA Scholar Study: Sensor-Navigated I-124-PET/US Fusion Imaging versus Conventional Diagnostics for Retrospective Functional Assessment of Thyroid Nodules by Medical Students.Sensors (Basel, Switzerland) · 2020Article
- Article
- Comparison between technetium-99m methoxyisobutylisonitrile scintigraphy and ultrasound in the diagnosis of parathyroid adenoma and parathyroid hyperplasia.Nuclear medicine communications · 2018Article
- Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Digestive diseases and sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo review the benefits of single photon emission computed tomography (SPECT)/computed tomography (CT) hybrid imaging for diagnosis of various endocrine disorders.
methodsWe performed MEDLINE and PubMed searches using the terms: "SPECT/CT"; "functional anatomic mapping"; "transmission emission tomography"; "parathyroid adenoma"; "thyroid cancer"; "neuroendocrine tumor"; "adrenal"; "pheochromocytoma"; "paraganglioma"; in order to identify relevant articles published in English during the years 2003 to 2015. Reference lists from the articles were reviewed to identify additional pertinent articles. Retrieved manuscripts (case reports, reviews, meta-analyses and abstracts) concerning the application of SPECT/CT to endocrine imaging were analyzed to provide a descriptive synthesis of the utility of this technology.
resultsThe emergence of hybrid SPECT/CT camera technology now allows simultaneous acquisition of combined multi-modality imaging, with seamless fusion of three-dimensional volume datasets. The usefulness of combining functional information to depict the bio-distribution of radiotracers that map cellular processes of the endocrine system and tumors of endocrine origin, with anatomy derived from CT, has improved the diagnostic capability of scintigraphy for a range of disorders of endocrine gland function. The literature describes benefits of SPECT/CT for (99m)Tc-sestamibi parathyroid scintigraphy and (99m)Tc-pertechnetate thyroid scintigraphy, (123)I- or (131)I-radioiodine for staging of differentiated thyroid carcinoma, (111)In- and (99m)Tc- labeled somatostatin receptor analogues for detection of neuroendocrine tumors, (131)I-norcholesterol (NP-59) scans for assessment of adrenal cortical hyperfunction, and (123)I- or (131)I-metaiodobenzylguanidine imaging for evaluation of pheochromocytoma and paraganglioma.
conclusionSPECT/CT exploits the synergism between the functional information from radiopharmaceutical imaging and anatomy from CT, translating to improved diagnostic accuracy and meaningful impact on patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.